Peptide therapy claims on TikTok: what the science supports

What did @dr..alex.tatem actually say?

The video features Dr. Larry Lipshultz explaining the basics of peptide science to a bodybuilding-adjacent TikTok audience. His core claims: peptides are proteins under 40 amino acids, anything above that threshold is a biologic subject to stricter FDA rules, peptides are "naturally occurring" rather than invented, BPC-157 comes from gastric secretions, kisspeptin is extracted from placentas, and the safety profile looks clean so far because "there doesn't appear to be any identifiable side effects." He also flags kisspeptin as a potential treatment for low male libido, while admitting he hasn't fully reviewed the research on it yet.

That last admission is worth noting: a physician publicly endorsing a compound he "hasn't looked into yet" is a red flag, even if the overall framing is cautious. Credit where it's due: he does say "early days" and avoids making hard efficacy claims. But the regulatory framing, the origin story for BPC-157, and the safety blanket he throws over the whole category deserve a closer look.

Does the science back this up?

Partially. The 40-amino-acid threshold as a regulatory cutoff is a real concept, but the FDA's actual framework is more complicated than a single number. On BPC-157's origins, the "extracted from gastric secretions" framing is misleading. On kisspeptin and libido, there is genuine early-stage data, but it is far from established.

The FDA distinguishes peptide drugs from biologics using a 40-amino-acid threshold in the Biologics Price Competition and Innovation Act context, but the practical regulatory picture is messier. Many synthetic peptides are regulated as drugs, not biologics, regardless of their natural origins. The claim that peptides are "slipping through the cracks" has some truth to it: the FDA's 2023 updates to its compounding rules specifically targeted certain peptides, including BPC-157, by removing them from the 503A bulk drug substances list, suggesting regulators are catching up fast (FDA, 2023).

On BPC-157: it is a synthetic peptide. It was identified based on a partial sequence of a protein found in gastric juice, but the compound used in research and clinical contexts is synthetically manufactured, not directly extracted. That distinction matters. Kisspeptin research in men is real but early: Dhillo et al. (2005, Journal of Clinical Endocrinology and Metabolism) established its role in the hypothalamic-pituitary axis, and there is small-scale human data on sexual function, but no approved indication exists.

What did they get wrong (or right)?

The biggest factual problem is the BPC-157 origin claim. Saying "someone didn't make it, someone extracted it" is incorrect for the compound as it exists in commercial and research settings. BPC-157 (PL 14736) is a synthetic 15-amino-acid peptide. Researchers identified a sequence in gastric proteins and synthesized a stable analog. Calling it "extracted" implies it comes straight from a biological source, which it does not. This is the kind of framing that makes peptides sound safer and more natural than the evidence justifies.

The regulatory claim is mostly right in spirit: peptides do occupy a gray zone, and enforcement has been inconsistent. But "no one knows what to do with them" undersells how actively the FDA has moved. The 2023 compounding guidance changes are a direct response to exactly this gap. The safety claim, "consequently, they don't have bad side effects," is the most dangerous line in the video. Absence of known side effects is not the same as absence of side effects. BPC-157 has no completed large-scale human clinical trials. Rodent studies are promising (Sikiric et al., 2018, Current Pharmaceutical Design), but rodent data does not translate cleanly to human safety profiles.

What he got right: the 40-amino-acid threshold concept, the acknowledgment that this is early-stage science, and the honest flag that kisspeptin research in men is underdeveloped compared to women.

What should you actually know?

If you are considering peptide therapy, the regulatory status of specific compounds matters more than a general "naturally occurring" reassurance. BPC-157 is not FDA-approved for any indication. As of 2023, it cannot be legally compounded under 503A pharmacy rules in the United States. That does not mean no one is selling it, it means anyone selling it is operating outside current federal guidance.

The safety argument from natural origin is a logical fallacy. Botulinum toxin is naturally occurring. So is arsenic. Origin does not determine safety profile. What determines safety is clinical trial data with human subjects at relevant doses over relevant timeframes. That data does not yet exist for most peptides discussed in the wellness space.

• Kisspeptin research in men is real but small-scale. A 2022 study by Comninos et al. in JCEM showed kisspeptin infusion increased sexual brain processing in men with hypoactive sexual desire, but this was a controlled infusion study, not an orally or subcutaneously dosed wellness protocol.
• Anyone telling you a peptide has no side effects because it is "natural" is conflating origin with safety data. Push back on that framing.
• The FDA's movement on compounding rules in 2023 signals that the regulatory gray zone is narrowing, not expanding.